Karolinska Development AB ser.B
Karolinska Development AB (publ): Karolinska Developments portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219
STOCKHOLM August 20, 2019. Karolinska Development (Nasdaq Stockholm:
KDEV) announces today that its portfolio company Forendo Pharma has
initiated dosing in a Phase 1b clinical study with the aim to demonstrate
Proof of Mechanism for FOR-6219 a drug candidate intended for the
treatment of endometriosis.
Endometriosis is a chronic condition that affects up to 10 per cent of
women in reproductive age and causes repeated pain symptoms, infertility
and impaired quality of life. Currently available treatments have
limitations in efficacy or cause harmful side effects due to estrogen
depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen
production locally in the endometriosis lesions.
In the Phase 1b study, FOR-6219 will be administered to healthy
premenopausal women to explore its effect on the endometrium by measuring
changes in endometrial thickness and endometrial estrogen levels. In
addition to these local effects, systemic hormone levels will be measured.
The study will also provide further safety and tolerability data.
A positive outcome of this important Phase 1b study would further
strengthen the hypothesis that Forendo Pharmas lead drug candidate has
potential to transform the treatment of endometriosis, based on its unique
ability to selectively inhibit local estrogen production, said Viktor
Drvota, CEO of Karolinska Development.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life
sciences investment company. The company focuses on identifying
breakthrough medical innovations in the Nordic region that are developed by
entrepreneurs and leadership teams. The Company invests in the creation and
growth of companies that advance these assets into commercial products that
are designed to make a difference to patients lives while providing an
attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research
institutes in the Nordic region. The Company aims to build companies around
scientists who are leaders in their fields, supported by experienced
management teams and advisers, and co-funded by specialist international
investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of ten companies
targeting opportunities in innovative treatment for life-threatening or
serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals
with a proven track record as company builders and with access to a strong
For more information, please visit www.karolinskadevelopment.com
* KD Press release Forendo August 2019